Canada Pension Plan Investment Board Puma Biotechnology, Inc. Transaction History

Canada Pension Plan Investment Board

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 12, 2019	SELL	$8.75 - $12.85 $202,238 - $297,002	-23,113 Closed	0 $0
Q2 2019 Aug 12, 2019	SELL	$12.3 - $35.76 $38,117 - $110,820	-3,099 Reduced 11.82%	23,113 $294,000
Q1 2019 May 15, 2019	SELL	$20.77 - $42.37 $535,616 - $1.09 Million	-25,788 Reduced 49.59%	26,212 $1.02 Million
Q4 2018 Feb 06, 2019	BUY	$20.07 - $46.7 $287,001 - $667,810	14,300 Added 37.93%	52,000 $1.06 Million
Q3 2018 Nov 09, 2018	BUY	$41.2 - $59.85 $1.55 Million - $2.26 Million	37,700 New	37,700 $1.73 Million
Q2 2018 Aug 07, 2018	SELL	$48.3 - $68.25 $1.84 Million - $2.6 Million	-38,100 Closed	0 $0
Q1 2018 May 14, 2018	BUY	$59.7 - $99.25 $179,100 - $297,750	3,000 Added 8.55%	38,100 $2.59 Million
Q4 2017 Feb 14, 2018	BUY	$93.85 - $132.45 $1.48 Million - $2.09 Million	15,800 Added 81.87%	35,100 $3.47 Million
Q3 2017 Oct 30, 2017	SELL	$72.0 - $119.75 $1.7 Million - $2.83 Million	-23,600 Reduced 55.01%	19,300 $2.31 Million
Q2 2017 Jan 31, 2018	SELL	N/A	-100 Reduced 0.23%	42,900 $3.75 Million
Q1 2017 Jan 31, 2018	BUY	N/A	43,000	43,000 $1.6 Million

100

29M

50.6K

16.3K

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $135M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

Get notified when there are updates to the investment portfolio of Canada Pension Plan Investment Board, based on Form 13F filings with the SEC.

Stay updated on Canada Pension Plan Investment Board with notifications on news.